BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Nohla Therapeutics to Acquire Clinical Grade Cord Blood Units from LifeSouth for Expanded HSC Products
Nohla Therapeutics - Cord Blood

Nohla Therapeutics to Acquire Clinical Grade Cord Blood Units from LifeSouth for Expanded HSC Products

October 21, 2016 By Cade Hildreth (CEO) Leave a Comment

Nohla TherapeuticsNohla Therapeutics has signed an exclusive supply agreement with LifeSouth Community Blood Centers headquartered in Gainesville, Florida. Under this agreement, LifeSouth’s cord blood banking program will supply Nohla Therapeutics with clinical grade cord blood units that will be used in the production process for the Company’s expanded hematopoietic stem and progenitor cell (HSC/HPC) products.

Discover class-defining bioproduction tools.

Nohla Therapeutics and LifeCord

The cord blood units to be provided to Nohla are ones that are unlikely to be promising for use in transplantation, because of a lower Total Nucleated Cell (TNC) count within the units. According to Nohla Therapeutics, “With the rising Total Nucleated Cell (TNC) count requirements desired by transplant centers, the majority of banked units may never be used for clinical transplantation due to their lower dosage.”

Therefore, there is mutual benefit to LifeSouth Community Blood Centers and Nohla Therapeutics in the agreement, because LifeSouth will get a predictable revenue stream, while Nohla will get acess to high-quality cord blood units processed in a FACT accredited, FDA licensed cord blood manufacturing facility.

Rooster DevServices

LifeSouth represents an excellent supply partner for Nohla Therapeutics, because of its credentials and long history. LifeSouth Community Blood Centers is a regional blood network that operates collection centers across Georgia, Florida, and Alabama. Additionally, its cord blood banking program “LifeCord” is FACT accredited, FDA licensed (2013), and has been collecting and processing cord blood units since in 1998. As of 2016, it now collects 8,000+ cord blood units annually from a dozen partner hospitals in spread across its operating states.

As stated within the Nohla’s recent announcement, “The agreement between LifeSouth and Nohla allows LifeSouth to generate revenue and recoup some of its banking costs while providing Nohla with fully qualified cord blood units for pooling as starting material for the Company’s expanded cellular therapy programs.”

bitbio

To learn more, click here to view the full press release issued by Nohla Therapeutics.

Rate this post

Filed Under: Cord Blood, HSCs, Stem Cell News Tagged With: cord blood research, LifeCord, Nohla Therapeutics, partnership

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.